TheDaoIndex KDAO2011
2 years 2 months ago
POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0
Nouf Al hemmadi NoufAhmedAlham2
2 years 2 months ago
Recommendation for management of fatigue in people with rheumatic disease.
Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it.
I will also add yearly blood work including:
1- VitD
2-HBA1c and LDl
3-TsH. https://t.co/3QvPqMxZSN
Rheumatology & Rheumatology Advances in Practice RheumJnl
2 years 2 months ago
Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀
➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx
Tuhina Neogi, MD, PhD Tuhina_Neogi
2 years 2 months ago
Mapping the knee #osteoarthritis joint-nerve interactome — presented by @AM_Malf at #EULAR2024. Anatomical and molecular neuroplasticity occurs during OA onset + progression in the joint and DRG. Cool imaging of nerves and their activity with lightsheet microscopy in mice https://t.co/cre6LEVhle
Nouf Al hemmadi NoufAhmedAlham2
2 years 2 months ago
Maintenance of remission in GPA/MPA.
RTX for 48 months sounds good to me.
#EULAR2024 https://t.co/5YGwOHhCuX
Annals of the Rheumatic Diseases ARD_BMJ
2 years 2 months ago
Potential efficacy of JAK inhibitors in VEXAS syndrome
#EULAR2024
NZ https://t.co/HziLUgo1gA
EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.
Aurelie Najm AurelieRheumo
2 years 2 months ago
500+ pts AxSPA
No difference in drug discontinuation between IL-17i, TNFi, IL23i over time
Adjusted for CRP, co-medication w/ MTX + classic covariates
IL-17i and IL-23i had experienced a higher number bDMARD failures
#EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
Aurelie Najm AurelieRheumo
2 years 2 months ago
Cohort from Netherlands 400+ PsA pts IR first bioDMARD
300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi
3year retention rates
12 mo 75% cyclers 80% swappers
24mo 60% cyclers 56% swappers
No difference in treatment failure or DAS28 CRP
#EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG
Aurelie Najm AurelieRheumo
2 years 2 months ago
What is the meaning of mechanical stress-induced sacroiliac BMO MRI after childbirth in healthy women?
5yrs follow up MRI study shows:
-decrease in BMO
-1/3 BMO @ 5-year follow-up
-15% ASAS definition of sacroiliitis
-No correlation w/ symptoms
@RheumNow #EULAR24 OP0222
Aurelie Najm AurelieRheumo
2 years 2 months ago
Understudied neurological involvement 🧠 in RA
in pts > 65 vs. matched HC
-larger lateral cerebral ventricles
-brain atrophy
-shrinkage of thalamus + frontal cortical regions
-association w/ clinical depression
@RheumNow POS0148 #EULAR2024 https://t.co/2mV4qGyBtW
Aurelie Najm AurelieRheumo
2 years 2 months ago
BARI reduces nociplastic pain, small cohort RA n=13
-wk 12 ACR FM score 14 vs 10.5 p=0.03
-fMRI data: reduction connectivity between DMN and posterior insula & between IPL & anterior/middle insular regions
Directs mechanims yet to be investigated
@RheumNow POS0310 #EULAR2024 https://t.co/jGgvS5qqV6
Aurelie Najm AurelieRheumo
2 years 2 months ago
Is RA always preceded by clinically suspect arthralgia? Cohort 650+ pts CSA = 83 pts no CSA = 616 pts
Pts w/ no CSA: -older -more frequent acute onset of symptoms -higher SJC -increased CRP -less ACPA+ No sure how accounted for memory bias
#EULAR2024 @RheumNow POS1030 https://t.co/dJeN41ax5P
